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Inositol-3-phosphate synthase (INO1) has previously been genetically validated as a drug target against Trypanosoma brucei,t h e
causative agent of African sleeping sickness. Chemical intervention of this essential enzyme could lead to new therapeutic agents.
Unfortunately, no potent inhibitors of INO1 from any organism have been reported, so a screen for potential novel inhibitors of
T. brucei INO1was undertaken. Detection of inhibition of T. brucei INO1 is problematic due to the nature of the reaction. Direct
detection requires diﬀerentiation between glucose-6-phosphate and inositol-3-phosphate. Coupled enzyme assays could give false
positives as potentially they could inhibit the coupling enzyme. Thus, an alternative approach of diﬀerential scanning ﬂuorimetry
to identify compounds that interact with T. brucei INO1 was employed to screen ∼670 compounds from the MayBridge Rule of
3 Fragment Library. This approach identiﬁed 38 compounds, which signiﬁcantly altered the Tm of TbINO1. Four compounds
showed trypanocidal activity with ED50s in the tens of micromolar range, with 2 having a selectivity index in excess of 250. The
trypanocidalandgeneralcytotoxicity activities ofallofthecompoundsinthelibrary arealsoreported, withthebest havingED50S
of ∼20μMa g a i n s tT. brucei.
1.Introduction
Human African Trypanosomiasis (HAT), also called African
sleeping sickness, is caused by the extracellular protozoan
parasite Trypanosoma brucei. HAT is a potentially fatal
disease with ∼200000 new cases per year in sub-Saharan
Africa [1]. Despite this, current drugs are often toxic and
diﬃcult to administer, highlighting the urgent need for new,
more eﬀective drug therapies. T. brucei is able to survive
in the hosts’ bloodstream due to a dense coat (5×106 dim-
ers/cell) of variant surface glycoprotein (VSG) [2, 3]. This
coat acts as a diﬀusion barrier and enables the cell to avoid
the hosts’ innate immune system by a specialised process of
antigenic variation, utilising a repertoire of more than 1000
diﬀerent VSG genes [4, 5]. Although the VSG coat is sys-
tematicallychanged,itisalwaysattachedtotheplasmamem-
brane via a glycosylphosphatidylinositol (GPI) anchor [6, 7].
GPI anchors are ubiquitous to eukaryotes and comprise of
t h eb a s i cc o r es t r u c t u r eo fN H 2CH2CH2PO4H-6Manα1-
2Manα1-6Manα1-4GlcNα1-6D-myo-inositol-1-HPO4-lipid
(EtN-P-Man3GlcN-PI),with a lipid moiety of diacylglycerol,
alkylacylglycerol, or ceramide [8]. Previously, the biosyn-
thesis of GPI anchors in bloodstream form T. brucei has been
both genetically and chemically validated as a therapeutic
drug target [9–11].
The de novo synthesis of myo-inositol is a ubiquitous
process occurring in almost all eukaryotes studied. It is the
result of the concerted actions of two enzymes: ﬁrstly an
D-myo-inositol-3-phosphate synthase (INO1) which isom-
erases glucose-6-phosphate to D-myo-inositol-3-phosphate
and secondly, an inositol monophosphatase which dephos-
phorylates the D-myo-inositol-3-phosphate to yield myo-in-
ositol [12]. Previously, through the creation of a condition-
al knockout cell line of INO1, it was demonstrated that2 Molecular Biology International
the de novo synthesis of myo-inositol is essential to the
survival of bloodstream form T. brucei [13, 14]. Surprisingly,
the deletion of INO1 couldnot be overcome by the inclusion
of extra myo-inositol in the media, which is in striking
contrast to all other INO1 null mutants described to date.
Intriguingly, further analysis showed that there was no
signiﬁcant decrease in the level of myo-inositol in the
conditional knockout cells grown under nonpermissive con-
ditions, showing that the cells were not exhibiting the typical
“inositol-less” death phenotype described for all other INO1
mutants[12,15,16].In vivo labelling andlocalisation studies
of INO1 [13, 14]a n dt h eT. brucei phosphatidylinositol
synthase [17] suggested that the de novo synthesised myo-
inositol is the primary source of myo-inositol used in the
formation of phosphatidylinositol for GPI anchors and
that there was a distinction or compartmentalisation of the
de novo synthesised myo-inositol from that obtained from
extracellular sources. The clear dependence by bloodstream
form T. brucei on de novo synthesised myo-inositol for GPI
anchor biosynthesis has not been described for any other
organism to date and shows a unique avenue which could be
exploited for future therapeutic drug design.
The MayBridge Rule of 3 Fragment Library (May Ro3)
is a relatively small collection of chemical entries that are
pharmacophore rich. The rule of 3 refers to compliance
to the following criteria: MW ≤ 300, cLogP ≤ 3.0, H-
Bond Acceptors ≤ 3, H-Bond Donors ≤ 3, Rotatable bonds
(Flexibility Index) ≤3, and Polar Surface Area ≤ 60 ˚ A[ 18].
Thelibrary has quantiﬁablediversitythroughtheapplication
of standard chemometrics, assured aqueous solubility to
≥1mM using LogS and high purity (≥95%).
As T. brucei INO1 (TbINO1) is a genetically validated
drugtargetand screening forinhibitorsisproblematicdueto
thenatureofthereaction and/ortheuseofacoupledenzyme
assay, diﬀerential scanning ﬂuorimetry was employed to
look for compounds that interact with TbINO1. Thus,
∼670 compounds from the May Ro3 fragment library were
screened and their trypanocidal and general cytotoxicactivi-
ties determined.
2.Experimental
2.1. Materials. All materials unless stated were purchased
either from Sigma/Aldrich or Invitrogen. Access to the May-
bridge Rule of 3 (May Ro3) library, was kindly provided
by Dr Rupert Russell (St Andrews). Stock solutions of the
compounds (2M) were prepared in DMSO and kept in
master plates at 200mM in DMSO (100%) by Dr Margaret
Taylor (St Andrews). These were replated into daughter
(working) plates occupying the central 80 wells of a 96-well
plate, at 10mM in 5% DMSO, allowing the two outside
columns for positive and negative controls.
2.2. TbINO1 Protein Overexpression and Puriﬁcation. Large-
scale recombinant expression and puriﬁcation of TbINO1
wasconductedusing theconstructpET15b-TbINO1inBL21
Rosetta (DE3) cells, and TbINO protein was puriﬁed by
Ni aﬃnity chromatography, eluted with 100mM imidazole,
20mM Tris pH 7.5, and 300mM NaCl. The His-tagged
protein was then dialysed against 20mM Tris pH 7.5,
50mM NaCl, 5mM DTT and stored with 20% glycerol, at
−80◦C for up to 12 months without loss of activity. Full
details of expression vector construction and puriﬁcation
will be published elsewhere (Martin, K. L. and T. K. Smith
unpublished).
2.3. Diﬀerential Scanning Fluorimetry with TbINO1. Diﬀer-
ential scanning ﬂuorimetry was set up in 96-well PCR plates
using a reaction volume of 100μL. Shifts in TbINO1 Tm
with ligand binding were observed when ammonium acetate
and NAD+ were present. Samples contained 2μM TbINO1,
2mM Ammonium Acetate, 1mM NAD+, 10mM HEPES
pH 7.5, 50mM NaCl, and 1.25 working stock of Sypro
Orange (Invitrogen, as a 5000 times stock). Compounds
from the May Ro3 fragment library (1mM) and positive
controls, glucose-6-phosphate as substrate (5mM) and 2-
deoxy-glucose-6-phosphate as inhibitor (4mM) were added
as required.
Diﬀerential ﬂuorimetric scans were performed in a real-
time PCR machine (Stratagene Mx3005P with software
MxPro v 4.01) using a temperature scan from 25◦Ct o
95◦Ca t0 . 5 ◦Cmin −1. Data were then exported to Excel for
analysis using “DSF analysis” modiﬁed from the template
provided by Niesen et al. [19]. Tm values were calculated by
nonlinear regression, ﬁtting the Boltzmann equation to the
denaturation curves using GraFit.
2.4. Cytotoxicity Studies. The trypanocidal activity of all
compounds (ﬁnal 0.5mM, 0.5% DMSO) against cultured
bloodstream T. brucei (strain 427) was determined using the
Alamar Blue viability test as described previously [20].
Cytotoxic eﬀects against HeLa and A549 cells were deter-
mined in a similar manner. Brieﬂy, the cells were cultured
in DMEM supplemented with 10% FCS and 2mM L-
Glutamine. Cells were plated at initial cell concentration of
2×104 cells/wellandincubatedwiththecompoundsfor ∼65
hours prior to addition of Alamar Blue solution for a further
5h o u r s .
3.Resultsand Discussion
3.1. Is TbINO1 Amenable to Diﬀerential Scanning Fluorime-
try? . Inositol-3-phosphate synthase has previously been
geneticallyvalidatedasadrugtargetagainstT. brucei [13,14],
and is a prime candidate for chemical intervention as a
therapeutic against African sleeping sickness. Unfortunately,
no potent inhibitors of INO1 from any organism have been
reported; therefore, it was decided to undertake a screen
for potential novel inhibitors of TbINO1. Screening for
inhibitors of TbINO1 is problematic due to the diﬃculty in
following the reaction, that is, having to directly diﬀerentiate
between glucose-6-phosphate and inositol-3-phosphate, or
alternatively using a coupled enzyme assay, where a com-
pound could potentially inhibit the coupled enzyme [14].
Thus, an alternative approach was taken, using diﬀerential
scanning ﬂuorimetry. Diﬀerential scanning ﬂuorimetry hasMolecular Biology International 3
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Figure 1: Typical diﬀerential ﬂuorimetry scans of TbINO1. Dif-
ferential ﬂuorimetric scans were performed and analysed as de-
scribed in Experimental. TbINO1+DMSO (control) dotted line,
TbINO1+4mM 2-deoxy-glucose-6-phosphate (positive control)
solid line, and TbINO1+1mM compound 520, dashed line.
beenusedtoidentifycompoundsthatinteractwithaprotein,
either to stabilise or destabilise it, and therefore inﬂuencing
the protein’s Tm (melting point) [21].
TbINO1 was subjected to diﬀerential scanning ﬂuorime-
try to ascertain if this approach was possible. The Tm for
TbINO1 was determined in the presence of NAD+ and
ammonium acetate, both known cofactors and stimuli of
INO1 activity [13, 14, 22]; in a typical experiment, Tms
were consistently ∼51.4◦C (4 samples, range 51.36–51.39◦C)
(Figure 1, dotted line). The substrate glucose-6-phosphate
(5mM) increased the Tm by 0.70±0.28◦C; however, 2-
deoxy-glucose-6-phosphate (4mM), a known inhibitor of
INO1s [22–24], increased the Tm value by +2.84±0.47◦C
(Figure 1, solid line). These encouraging results allowed
validationofascreeningprogram;thus,glucose-6-phosphate
and 2-deoxy-glucose-6-phosphate were used as positive con-
trols, and DMSO (in which all compounds were dissolved)
as a negative control on all subsequent screening plates.
3.2. Screening of the May Ro3 Fragment Library for Com-
pounds That Interact with Tbino1 by Diﬀerential Scanning
Fluorimetry. As TbINO1 was amenable to screening by dif-
ferential scanning ﬂuorimetry, ∼670 compounds from the
May Ro3 fragment library were screened. Additionally, their
trypanocidal and general cytotoxicity activities, against
bloodstream T. brucei and HeLa and A549 cells were assessed
(see Supplementary Table 1 in Supplementary Material
available online at doi: 10.4061/2011/389364).
From this large amount of data, 38 compounds at 1mM
interacted with TbINO1 with a ΔTm > +1.5◦C( Table 1). Of
these compound 520, 2-(2-furyl)benzoic acid, stabilised the
protein the greatest with a ΔTm +4 .29 ± 0.07◦C( Figure 1,
dashed line). It is interesting to note that the heterocyclic
furan moiety is a common feature in several of the top hits
(Table 1, compounds 520, 75, 30, 28, and 383).
Other similarities between the top hits are the presence
of a carboxylic acid (Table 1, compounds 520, 75, 28, 513)
or a methanol group (Table 1, compounds 186, 30, 383)
attached to an aromatic ring. An obvious conclusion is
that these moieties form important hydrogen bonds to the
protein, in a similar orientation to each other with respect to
the aromatic ring to which they are attached.
The trypanocidal and cytotoxicity activities of these 38
compounds (Table 1) revealed that 9 of them killed more
than 35% of T. brucei at 0.5mM. These were investigated
further, and their ED50s for both T. brucei and HeLa cells
were determined (Table 1). Of these compound 162, 1H-
indol-3-ylmethanol with a ΔTm +2.31±0.06◦C( Table 1),
was the most potent with an ED50 of 31±1.4μM, but
was also cytotoxic against HeLa cells, ED50 of 103±6μM,
thus giving a very poor selectivity index of 3.3. However,
another compound 256, 2-quinolinylmethanol, structurally
very similar to compound 162, that has an ED50 of
40.1±1.2μM, showed less cytotoxicity against HeLa cells,
giving a selectivity index of ∼21.
Interestingly, the top TbINO1 diﬀerential scanning ﬂuo-
rimetry hit, compound 520, also showed trypanocidal activ-
ity, ED50 of 76±6μM, but no cytotoxicity towards HeLa
cellsat20mM,thusgiving aselectivity index >256.However,
the best selectivity index from these TbINO1 diﬀerential
scanning ﬂuorimetry hits (Table 1) was compound 239, 2-
amino-4-methylthiophene-3-carboxamide, with a T. brucei
ED50 of 63±2.5μM and a selectivity index >317.
It is interesting to note that compound 520 contains
a carboxylic acid and, therefore, should be impervious to
membranes by passive diﬀusion; this seems to be true for the
close analogous compound 513, 2-(1H-pyrrol-1-yl)benzoic
acid, which also interacts with TbINO1 strongly but has
no trypanocidal or general cytotoxicity activity at 0.5mM
(Table 1).
Puzzlingly, this suggests that some carboxylic acid con-
taining compounds, such as 520, may be speciﬁcally and
actively taken up by T. brucei, while other closely related car-
boxylic acid containing compounds are not.
The TbINO1 diﬀerential scanning ﬂuorimetry hits will
be investigated further in the future, as outlined in the con-
clusions.
3.3. Screening of the May Ro3 Fragment Library for Trypanoci-
dal Compounds. The most potent trypanocidal compounds
(ED50s<100μM) of the ∼670 compounds from the May
Ro3 fragment library (Supplementary Table 1) were inves-
tigated further by determining their ED50s in both T. brucei
and HeLa cells (Table 2). From ﬁrst observations, it is clear
that the vast majority of these compounds contain a primary
amine, with the most potent compounds (ED50s<40μM),
269, 270, and 348, containing an aromatic primary amine.
Unfortunately, most of the primary amine containing com-
pounds are cytotoxic and thus have poor selectivity indexes
(0.5–21). The only exceptions are compounds 520 and 239
(bothofwhich donotcontainaprimary amine),asdiscussed
earlier, andshowed nocytotoxicityat20mM(Tables1and2)
with selectivity indexes greater than 260.
The structure activity relationship of the most potent
trypanocidal compound from the library, compound 2694 Molecular Biology International
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Table 2: Screening for trypanocidal compounds in the MayBridge Rule of 3 Fragment Library.
Library numbera Molecular structure T. brucei ED50b (μM) HeLa ED50b (μM) Selectivity index
269
F 
Cl
NH2
NH2
20.1±1.0 431±53 21.4
270
F
F
F
NH2
30.5±1.6 206±13 6.8
162
N
H
OH
31±1.4 103±63 . 3
348
N
NH2
35.0±1.0 21.8±1.8 0.6
256
N
OH
40.1±1.2 836±68 20.8
281 N 
N 
CH3
NH2
44.7±1.8 659±65 14.7
365
N
NH2
49.4±2.1 71.8±3.7 1.5
213
O O
CH3
NH2
C H3
55.6±1.3 710±96 12.8
257
O
NH2
56.0±3.6 114±82 . 0
239
S
   
O 
C H3
NH2
NH2
63.0±2.5 >20mM >317Molecular Biology International 11
Table 2: Continued.
Library numbera Molecular structure T. brucei ED50b (μM) HeLa ED50b (μM) Selectivity index
364
N 
NH2 63.2±1.7 40.4±1.8 0.6
520
OH   O 
O  76±6 >20mM >266
250
N 
NH2
81.0±5.1 1.4±0.1mM 17.1
325
N
S
  C H3 NH2
82.2±4.6 415±24 5
aArbitrary Library number.
bFor trypanocidal and cytotoxicity activity, see Section 2 for details and values are ED50s±SD (n = 4).
cSelectivityindex: T. brucei ED50/HeLa ED50.
(4-chloro-5-ﬂuorobenzene-1,2-diamine), with an ED50 of
20.1±1.03μM, was investigated further. A series of ana-
logues were purchased and tested in parallel; this included
analogues that had the two amino groups, but with only one
ofthehalidesoroneofthehalidesreplacedbyamethylgroup
or no halides. Other analogues maintained the halides, and
reduce the amino groups to one, or by masking both free
amines as a benzimidazole.
T. brucei and HeLa cellED50svalueswere determinedfor
this collection of compounds (Table 3).
Repurchased compound269,gaveED50ssimilar tothose
obtained earlier (20.1±1.03 and 31.1±1.22μM). As to the
structure activity relationship of the analogues, it is apparent
that the two amino groups seem to be important for potent
trypanocidal activity, as both compounds 269b and 269d
have dramatically increased ED50s.
The presence of two bulky groups opposite to the amine
groups seems detrimental as shown by compound 240 (4-
chloro-5-methylbenzene-1,2-diamine); a compound from
the May Ro3 fragment library (Supplementary Table 1).
The absence of one or both of the halides does not
alter the T. brucei ED50s dramatically, as demonstrated
by compound 269a (benzene-1,2-diamine), with an ED50
of 35.2±3.0μM( Table 3). The HeLa cell cytotoxicity of
various benzene-1,2-diamine analogues varies dramatically,
however the selectivity indexes are poor, the best being
the original compound 269, 4-chloro-5-ﬂuorobenzene-1,2-
diamine, with a selectivity index of ∼21 (Table 3)
Unfortunately, the benzene-1,2-diamine analogues are
thought to be carcinogenic, as they are suspected to be able
to interchelate DNA, although direct proof of this is still
lacking [25]. These diamines are also well known to form
Schiﬀ bases and are often used for derivatisation of natural
ketones and aldehydes, such as methglyoxal [26]. Ironically,
it is also this Schiﬀ base capability, which has led them
to be investigated as possible anticancer, antibacterial,
antifungal and antiviral agents [27, 28]. Either or both of
the DNA interchelating, or Schiﬀ base capabilities could be
t h ep o s s i b l em o d eo fa c t i o nf o rt h et r y p a n o c i d a la c t i v i t y .
To avoid the obvious possible problems associated with
carcinogenic compounds, while still maintaining the dual
functionality that seems to be important for potency,
compound 269e (2-amino-1-hydroxy-benzene or 2-amino-
phenol), was purchased and tested. This proved to be the
most potent trypanocidal agent tested in this study with an
ED50 of20.0±0.3μM; however, it was cytotoxicto the HeLa
cells (Table 3). Despite this, the relatively simple molecule
(2-amino-phenol) has been shown to have anti-microbial
activity [29, 30].
Consideringtheseareverysimple molecules,itis surpris-
ing that they are trypanocidal at low-micromolar concentra-
tions, highlighting the importance of screening programs to
identify novel pharmacophores.
4.Conclusions
In this work, screening of a comparatively small fragment
library forthermalstabilisation ofTbINO1hasallowed iden-
tiﬁcation of several novel compounds that interact strongly12 Molecular Biology International
Table 3: Structure activity relationship for trypanocidal activity of analogues of the diamine compound 269.
Library numbera CAS numberb Molecular structure T. brucei ED50c (μM) HeLa ED50c (μM) Selectivity indexd
269 139512-70-2
F 
Cl
NH2
NH2
20.1±1.2 431±53 21.4
269e 51-19-4 or 95-55-6
OH   
NH2
20.0±0.3 68.2±3.2 3.4
269c 95-83-0
Cl
NH2
NH2
21.9±1.2 224±35 10.2
269a 95-54-5
NH2
NH2
35.2±3.0 32.9±2.5 0.9
240 63155-04-4
 
Cl NH2
NH2 C H3
86.6±4.8 454±55 5.2
269b 367-22-6
Cl
F  NH2
150±13 1.4±0.1mM 9.3
269d 175135-04-3
Cl
F 
N 
H 
N 
331±24 520±52 1.6
aArbitrary Library number.
bCASnumbersare uniqueidentiﬁersassignedby the “ChemicalAbstractsService”to describeevery chemicaldescribedin theopen accessscientiﬁcliterature.
cFor trypanocidal and cytotoxicity activity, see Section 2 for details and values are ED50s±SD (n = 4).
dSelectivity index: T. brucei ED50/HeLa ED50.
and stabilise TbINO1. Unexpectedly, several of the signiﬁ-
cant hits are also trypanocidal with ED50 values in the 30–
80μM range, despite being relative simple molecules.
Several other compounds from the May Ro3 library
showed low-micromolar trypanocidal activity. The majority
of the most potent hits contain primary amines whose mode
of action could be via Schiﬀ-base formation, while some of
the diamines could also be acting by inter-chelating DNA,
thus interfering with cell-cycle progression/cell division.
Unfortunately, some of these compounds are cytotoxic
against mammalian cells and thus are unlikely to progress
as lead compounds. However, the biological activity of
related compounds such as 269e (2-amino-phenol), also
known to have anti-microbial activity, will be investigated
further.
Future work outside the scope of this study will include
the following:
(i) investigating if the lead compounds that interacted
with TbINO1 inhibit its activity, in an in vitro cou-
pled enzyme assay,
(ii) investigating the mode of killing by the lead com-
pounds that interacted with TbINO1 by undertaking
various in vivo labelling experiments to ascertain
if they are inhibiting TbINO1, thus causing a lack
of de novo synthesised myo-inositol, required for PI
synthesis for the essential GPI pathway,
(iii) the direct interactions of compounds with TbINO1
will be investigated by protein crystallography stud-
ies.Molecular Biology International 13
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